AstraZeneca plans to start early and mid-stage clinical trials of its COVID-19 vaccine candidate in China this year, as reported in The Guardian.
The vaccine candidate is already in the final stage of clinical trials in other countries, and AstraZeneca and partner Oxford University expect data from the late-stage trials this year.
If successful, they will file for emergency approvals in as many countries as possible at the same time, CEO Pascal Soriot said recently.
In China, the company has a deal with Shenzhen Kangtai Biological Products to manufacture the vaccine in the country.
Under the agreement, Shenzhen Kangtai will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222 by the end of this year.
The vaccine may be approved for use in China by mid-2021 after gathering safety data from Phase I and II trials in China and efficacy data from Phase III testing overseas, according to Leon Wang, head of AstraZeneca's China operations.
To read more NewsPoints articles, click here.